share_log

Bio-Rad Laboratories (NYSE:BIO.B) Sees Large Volume Increase

Bio-Rad Laboratories (NYSE:BIO.B) Sees Large Volume Increase

Bio-Rad 实验室(纽约证券交易所代码:BIO.B)预计交易量大幅增加
Financial News Live ·  2023/05/04 13:02

Bio-Rad Laboratories, Inc. (NYSE:BIO.B – Get Rating) saw unusually-high trading volume on Thursday . Approximately 200 shares traded hands during trading, an increase of 2,757% from the previous session's volume of 7 shares.The stock last traded at $467.95 and had previously closed at $467.95.

Bio-Rad Laboratories, Inc.(纽约证券交易所代码:BIO.B — 获取评级)周四的交易量异常高。交易期间约有200股交易,较前一交易日的7股交易量增加了2,757%。该股最后一次交易价格为467.95美元,此前收于467.95美元。

Analyst Ratings Changes

分析师评级变化

Separately, TheStreet raised shares of Bio-Rad Laboratories from a "d+" rating to a "c-" rating in a report on Monday, March 27th.

另外,TheStreet在3月27日星期一的一份报告中将Bio-Rad Laboratories的股票评级从 “d+” 上调至 “c-” 评级。

Get
获取
Bio-Rad Laboratories
生物射线实验室
alerts:
警报:

Bio-Rad Laboratories Stock Performance

Bio-Rad 实验室股票表现

The company has a market capitalization of $13.85 billion, a PE ratio of -3.85 and a beta of 0.66. The business's 50-day moving average is $443.89 and its 200-day moving average is $414.16. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.29 and a current ratio of 5.55.

该公司的市值为138.5亿美元,市盈率为-3.85,beta值为0.66。该公司的50天移动平均线为443.89美元,其200天移动平均线为414.16美元。该公司的债务与权益比率为0.12,速动比率为4.29,流动比率为5.55。

Bio-Rad Laboratories (NYSE:BIO.B – Get Rating) last issued its earnings results on Thursday, February 16th. The company reported $3.31 earnings per share (EPS) for the quarter. The business had revenue of $730.29 million during the quarter. Bio-Rad Laboratories had a negative net margin of 129.66% and a positive return on equity of 4.59%.

Bio-Rad Laboratories(纽约证券交易所代码:BIO.B — 获取评级)最后一次发布财报是在2月16日星期四。该公司报告了本季度每股收益(EPS)3.31美元。该业务在本季度的收入为7.3029亿美元。Bio-Rad Laboratories的负净利润率为129.66%,正股本回报率为4.59%。

Bio-Rad Laboratories Company Profile

Bio-Rad 实验室公司简介

(Get Rating)

(获取评分)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Bio-Rad Laboratories, Inc 在美国、欧洲、亚洲、加拿大和拉丁美洲生产和分销生命科学研究和临床诊断产品。该公司通过生命科学和临床诊断部门运营。生命科学部门开发、制造和销售一系列用于研究技术、生物制药生产过程和食品测试制度的试剂、设备和实验室仪器。

Featured Articles

精选文章

  • Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO.B)
  • How to Invest in Central Bank Digital Currency
  • Kellogg Company Looks GRRR-eat! At These Levels
  • PacWest, First Horizon Shares Plummet On Continued Bank Worries
  • Yum! Brands Pulls Back To More Appetizing Levels
  • Is it Time for Qualcomm to Start Playing Catch-up?
  • 免费获取 StockNews.com 关于 Bio-Rad 实验室 (BIO.B) 的研究报告
  • 如何投资中央银行数字货币
  • Kellogg 公司看起来吃了 GRR-eat!在这些级别
  • 由于银行持续担忧,PacWest、First Horizon股价暴跌
  • 好极了!品牌回落到更具吸引力的水平
  • 现在是高通开始追赶的时候了吗?

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收 Bio-Rad 实验室的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Bio-Rad Laboratories及相关公司的最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发